

Linfoepitelioma – Nasofaringe

Quimioterapia + Radioterapia

Cisplatina: 100 mg/m² IV D1, 22 e 43 durante radioterapia
Após o término da quimio e radioterapia a quimioterapia segue com o seguinte protocolo:

Cisplatina: 80 mg/m² IV D1

5-Fluorouracil: 1,000 mg/m²/dia IV infusão contínua D1-4
a cada 28 dias por um total de 3 ciclos

Ref. (12)

PBF

Cisplatina: 100mg/m² IV D1

Bleomicina: 15 mg IV D1

Bleomicina: 16mg/m²/dia em infusão contínua D1 a D5

Fluorouracil 650mg/m²/dia IV D1 a D5

a cada 28 dias

Ref. (23)

Paclitaxel concomitante a radioterapia

Paclitaxel: 35mg/m² IV semanal por 6 semanas

Após término da radioterapia:

Paclitaxel: 135mg/m² IV D1

Cisplatina: 30mg/m² IV D1 a D3

a cada 4 semanas por 2 ciclos

Ref. (24)

Cisplatina + Epirrubicina

Cisplatina: 100mg/m² IV D1

Epirrubicina: 90mg/m² IV D1 a cada 21 dias

Repetir por 3 ciclos seguidos por radioterapia concomitante a

Cisplatina: 100mg/m² IV a cada 21 dias

Ref. (25)

Capecitabina + Cisplatina

Capecitabina: 1000mg/m² VO BID D1 a D14

Cisplatina: 80 mg/m² IV D1

a cada 3 semanas

Ref. (26)

Gencitabina

Gencitabina: 1000mg/m² IV D1,8,15

a cada 4 semanas

Ref. (27)

Docetaxel + Cisplatina

Docetaxel: 60mg/m² IV D1

Cisplatina: 60mg/m² IV D1

a cada 3 semanas

Ref. (28)

Gencitabina + Cisplatina

Gencitabina: 1000mg/m² IV D1,8,15

Cisplatina: 50mg/m² IV D1 e D8

a cada 28 dias

Ref. (29)

Ifosfamida + 5-Fluorouracil + Leucovorin

Ifosfamida: 1.200 mg/m² (associado a Mesna) IV D1 a D5

5-Fluorouracil: 375mg/m² IV D1 a D5

Leucovorin: 20mg/m² IV D1 a D5

a cada 21 dias

Ref. (30)

BEC

Bleomicina: 15mg IV D1 seguido por 12mg/m²/dia em infusão contínua D1 a D5

Epirrubicina: 70mg/m² IV D1

Cisplatina: 100mg/m² IV D1

a cada 3 semanas

Ref. (31)

Carboplatina + 5-Fluorouracil

Carboplatina: 300 mg/m² IV D1

5-Fluorouracil: 1000 mg/m² IV D1 a D3 Infusão contínua
a cada 21 dias por 3 ciclos

Ref. (36)

Carboplatina + Paclitaxel

Carboplatina: AUC 6 IV pulso D1

Paclitaxel: 135 mg/m² IV D1 a cada 21 dias por 6 ciclos

Ref. (37)

Cisplatina + Epirrubicina + Bleomicina (BEC)

Cisplatina: 100 mg/m² IV D1

Epirrubicina: 80 mg/m² IV D1

Bleomicina: 15 mg IV pulso D1

Bleomicina: 16 mg/m² IV D1 a D5 Infusão
contínua a cada 28 dias por 3 ciclos

Ref. (38)

Docetaxel semanal

Docetaxel: 40 mg/m² IV D1 Semanal

Ref. (39)

1. Forastiere AA. *et al.* Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. *N Engl J Med* 349:2091, 2003.
2. Bonner JA. *et al.* Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck. *N Engl J Med* 2006; 354:567-578.
3. Vermorken JB *et al.* Cisplatin, Fluorouracil, and Docetaxel in Unresectable Head and Neck Cancer. *N Engl J Med* 357: 1695,2007.
4. Shin DS, *et al.* Phase II trial of paclitaxel, ifosfamide, and cisplatin in patients with recurrent head eneck squamous cell carcinoma. *J Clin Oncol* 1998;16:1325-1330.

5. Shin DM, *et al.* Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head neck squamous cell carcinoma of the head neck (SCCHN). *Cancer* 1999; 91:1316-1323.
6. Fountzilas G, *et al.* Paclitaxel and carboplatin in recurrent or metastatic head and neck cancer: a phase II study. *Semin Oncol* 1997; 24 (Suppl 2):65-67.
7. Hitt R, *et al.* A phase I/II study of paclitaxel plus cisplatin as firstline therapy fo rhead and neck cancer. *Semin Oncol* 1995;22 (Suppl 15):50-54.
8. Kish JA, *et al.* Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. *Cancer* 1984;53:1819-1824.
9. Vokes EE, *et al.* Cisplatin, 5-fluorouracil, and high-dose oral leucovorin for advanced head and neck cancer. *Cancer* 1989;63 (Suppl 6):1048-1053.
10. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. *N Engl J Med* 1991;324: 1685-1690.
11. Forastiere AA, *et al.* Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med* 2003;349:2091-2098.
12. Al-Sarraf M, *et al.* Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized intergroup study 0099. *J Clin Oncol* 1998;16:1310-1317.
13. Forastiere AA, *et al.* Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head neck: a Southwest Oncology Group study. *J Clin Oncol* 1992;10:1245-1251.
14. Gebbia V, *et al.* Vinorelbine plus cisplatin in recurrent or previously untreated unresectable squamous cell carcinoma of the head and neck. *Am J Clin Oncol* 1995;18:293-296.

15. Dreyfuss A, *et al.* Taxotere for advanced, inoperable squamous cell carcinoma of the head and neck (SCCHN). *Proc Am Soc Clin Oncol* 1995;14:875a.
16. Forastiere AA. Current and future trials of Taxol (paclitaxel) in head and neck cancer. *Ann Oncol* 1994;5 (Suppl 6):51–54.
17. Hong WK, *et al.* Chemotherapy in head and neck cancer. *N Engl J Med* 1983;308:75-79.
18. Degardin M, *et al.* An EORTC-ECSG phase II study of vinorelbine in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. *Ann Oncol* 1998; 9:1103-1107.
19. Vermorken JB, *et al.* Platinum Based Chemotherapy plus cetuximab in Head and neck cancer. *N Engl J Med* 2008; 359:1116.
20. van Herpen CM, *et al.* Phase II study on gemcitabine in recurrent and/or metastatic adenoid cystic carcinoma of the head and neck (EORTC 24982). *Eur J Cancer*. 2008 Nov; 44(17):2542-5.
21. Martinez-Trufero J, Isla D, Adansa JC *et al.* Phase II study of capecitabine as palliative treatment for patients with recurrent and metastatic squamous head and neck cancer after previous platinum-based treatment. *Br J Cancer*. 2010 Jun 8;102(12):1687-91.
22. Martín M, Diaz-Rubio E *et al.* Ifosfamide in advanced epidermoid head and neck cancer. *Cancer Chemother Pharmacol*. 1993;31(4):340-2.
23. Boussea H, Cvitkovic E, Wendling JL *et al.* Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. *J Clin Oncol*. 1991 Sep;9(9):1675-81
24. Hu W, Ding W, Yang H, Shao M. *et al.* Weekly paclitaxel with concurrent radiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma. *Radiother Oncol*. 2009 Dec; 93(3):488-91.
25. Airolidi M, Gabriele AM, Garzaro M *et al.* Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced

- nasopharyngeal carcinoma observed in a non-endemic population. *Radiother Oncol*. 2009 Jul;92(1):105-10.
26. Li YH, Wang FH, Jiang WQ *et al*. Phase II study of capecitabine and cisplatin combination as first-line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. *Cancer Chemother Pharmacol*. 2008 Aug; 62(3): 539-44.
 27. Zhang L, Zhang Y *et al*. Phase II clinical study of gemcitabine in the treatment of patients with advanced nasopharyngeal carcinoma after the failure of platinum-based chemotherapy. *Cancer Chemother Pharmacol*. 2008 Jan;61(1):33-8
 28. Chua DT, Sham JS, Au GK. A phase II study of docetaxel and cisplatin as first-line chemotherapy in patients with metastatic nasopharyngeal carcinoma. *Oral Oncol*. 2005 Jul;41(6):589-95.
 29. Ngan RK, Yiu HH, Lau WH *et al*. Combination gemcitabine and cisplatin chemotherapy for metastatic or recurrent nasopharyngeal carcinoma: report of a phase II study. *Ann Oncol*. 2002 Aug;13(8):1252-8.
 30. Chua DT, Kwong DL, Sham JS, Au GK, Choy D. A phase II study of ifosfamide, 5-fluorouracil and leucovorin in patients with recurrent nasopharyngeal carcinoma previously treated with platinum chemotherapy. 2000 Apr;36(6):736-41.
 31. No authors listed. Preliminary results of a randomized trial comparing neoadjuvant chemotherapy (cisplatin, epirubicin, bleomycin) plus radiotherapy vs. radiotherapy alone in stage IV(> or = N2, M0) undifferentiated nasopharyngeal carcinoma: a positive effect on progression-free survival. International Nasopharynx Cancer Study Group. VUMCA I trial. *Int J Radiat Oncol Biol Phys*. 1996 Jun 1;35(3):463-9.
 32. Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. *N Engl J Med* 1991;324:1685-90.
 33. Forastiere AA *et al*. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. *N Engl J Med* 2003;349:2091-2098.

34. Hitt R, *et al.* Randomized phase I/II clinical trial of induction chemotherapy with either cisplatin / 5-fluorouracil (PF) or docetaxel /cisplatin / 5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. CRT alone form in patients with unresectable locally advanced head and neck cancer (abst 5515). *J Clin Oncol.* 2006;24 Suppl 18: 283s.
35. Hitt R, *et al.* Phase III Study Comparing Cisplatin Plus Fluorouracil to Paclitaxel, Cisplatin, and Fluorouracil Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Head and Neck Cancer. *J Clin Oncol* 2005;23:8636-45.
36. Yeo W. *et al.* Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. *Cancer Chemother Pharmacol* 1996;38:466-70.
37. Yeo W.*et al.* A phase II study of combination paclitaxel and carboplatin in advanced nasopharyngeal carcinoma. *Eur J Cancer* 1998;34:2027-31.
38. Fandi A, *et al.* Long-Term Disease-Free Survivors in Metastatic Undifferentiated Carcinoma of Nasopharyngeal Type. *J Clin Oncol* 2000;18:1324-30.
39. Guardiola E, *et al.* Results of a randomized phase II study comparing docetaxel with methotrexate in patients with recurrent head and neck cancer. *Eur J Cancer* 2004;40:2071-6.
40. Fountzilias G, *et al.* Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group. *Ann Oncol* 2006;17:1560-7.
41. Fountzilias G, *et al.* Paclitaxel and gemcitabine vs. paclitaxel and pegylated liposomal doxorubicin in advanced non-nasopharyngeal head and neck cancer. An efficacy and cost analysis randomized study conducted by the Hellenic Cooperative Oncology Group *Ann Oncol* 2006;17:1560-7.